MAXVAX, a standout player in the biotechnology and healthcare space, attracted CNY300.00M in Series C investment from Shenzhen Venture Capital on 06 February 2024. The company's solid foundation since its establishment in 2016 reaffirms its commitment to pioneering advancements in biotechnology and healthcare. MAXVAX's recent funding success marks a significant milestone in its journey, positioning the company for substantial growth and impact in the healthcare industry.
MAXVAX
Founded 2016
Series C
Total: $1.40B
Biotechnology, Health Care
General Information
Company Name
MAXVAX
Founded Year
2016
Industries
Biotechnology, Health Care
Funding Stage
Series C
BounceWatch is an independent company data service, not affiliated with MAXVAX. To contact MAXVAX, visit maxvax.cn.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
Discover More
Biotechnology
About MAXVAX
Funding Rounds & Investors (5)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series C | CNY300.00M | 3 |
|
15 Jun 2024 |
| Series C | CNY300.00M | 1 |
|
06 Feb 2024 |
| Series B | CNY300.00M | 4 |
|
07 Dec 2022 |
| Series B | CNY500.00M | 2 |
Fangshizhen Capital, China Life Private Equity Investment
|
22 Jul 2022 |
| Series A | Undisclosed | - |
|
20 Jul 2021 |
FAQ About MAXVAX
MAXVAX was founded in 2016.
MAXVAX operates in Biotechnology and Health Care.
MAXVAX has completed 5 funding rounds, raising a total of $1.40B. The latest funding stage is Series C.
We're actively collecting intelligence on MAXVAX.
Source: BounceWatch company record for MAXVAX, https://bouncewatch.com/company/maxvax, updated 26 July 2024. When citing, please name BounceWatch and link this page.
